- Home
- TXMD vs KPRX Comparison
TXMD vs KPRX Comparison
Compare TXMD & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- KPRX
- Stock Information
- Founded
- TXMD 2008
- KPRX 1998
- Country
- TXMD United States
- KPRX United States
- Employees
- TXMD N/A
- KPRX N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TXMD Health Care
- KPRX Health Care
- Exchange
- TXMD Nasdaq
- KPRX Nasdaq
- Market Cap
- TXMD 12.8M
- KPRX 12.0M
- IPO Year
- TXMD N/A
- KPRX N/A
- Fundamental
- Price
- TXMD $1.00
- KPRX $3.87
- Analyst Decision
- TXMD
- KPRX Strong Buy
- Analyst Count
- TXMD 0
- KPRX 1
- Target Price
- TXMD N/A
- KPRX $10.00
- AVG Volume (30 Days)
- TXMD 113.1K
- KPRX 42.1K
- Earning Date
- TXMD 03-28-2025
- KPRX 03-24-2025
- Dividend Yield
- TXMD N/A
- KPRX N/A
- EPS Growth
- TXMD N/A
- KPRX N/A
- EPS
- TXMD N/A
- KPRX 1.69
- Revenue
- TXMD $1,596,000.00
- KPRX $16,020,000.00
- Revenue This Year
- TXMD $605.07
- KPRX N/A
- Revenue Next Year
- TXMD $1.11
- KPRX N/A
- P/E Ratio
- TXMD N/A
- KPRX $2.25
- Revenue Growth
- TXMD N/A
- KPRX N/A
- 52 Week Low
- TXMD $0.70
- KPRX $3.00
- 52 Week High
- TXMD $2.75
- KPRX $7.65
- Technical
- Relative Strength Index (RSI)
- TXMD 41.47
- KPRX 54.01
- Support Level
- TXMD $0.99
- KPRX $3.50
- Resistance Level
- TXMD $1.13
- KPRX $4.14
- Average True Range (ATR)
- TXMD 0.06
- KPRX 0.25
- MACD
- TXMD -0.00
- KPRX 0.02
- Stochastic Oscillator
- TXMD 5.26
- KPRX 70.19
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.